INTRABON
MRP: 7,990
Packaging: 10x1x10
Pack Type: tablet
Composition:
Bosentan 62.5mg
Indication:
Pulmonary arterial hypertension
Description:
Bosentan 62.5 mg** is an endothelin receptor antagonist (ERA) used primarily for the treatment of pulmonary arterial hypertension (PAH). It works by blocking endothelin-1 receptors (ETA and ETB), a substance in the blood vessels that causes them to narrow. By blocking these receptors, Bosentan relaxes the blood vessels, improving blood flow and reducing the workload on the heart.
It is also prescribed to manage systemic sclerosis-related digital ulcers and may be used in off-label indications under medical supervision.
Tags:
- Reduces pulmonary artery pressure
- Improves exercise capacity and symptoms in PAH
- Delays disease progression
- Helps heal and prevent digital ulcers
- Enhances quality of life in PAH patients
Usage Information
Dosage
Initial dose: 62.5 mg twice daily for 4 weeks Then, maintenance dose may be increased to 125 mg twice daily as per doctor’s advice Take with or without food Regular liver monitoring is mandatory Note: Always use under the guidance of a physician experienced in treating PAH.
Side Effects
Common: Headache Flushing Anemia Respiratory infections Nasal congestion Serious: Hepatotoxicity (elevated liver enzymes) Decrease in hemoglobin/hematocrit Teratogenicity – can cause birth defects Swelling of ankles/feet (fluid retention)
Contraindications
Pregnancy – category X (must use reliable contraception) Known hypersensitivity to Bosentan Moderate to severe hepatic impairment Concurrent use with cyclosporine A or glyburide Breastfeeding women